Ubrogepant for the Treatment of Migraine
Top Cited Papers
- 5 December 2019
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 381 (23), 2230-2241
- https://doi.org/10.1056/nejmoa1813049
Abstract
Ubrogepant is an oral, small-molecule calcitonin gene–related peptide receptor antagonist for acute migraine treatment.Keywords
This publication has 16 references indexed in Scilit:
- BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trialCephalalgia, 2013
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineCephalalgia, 2011
- BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II studyCephalalgia, 2010
- CGRP and its receptors provide new insights into migraine pathophysiologyNature Reviews Neurology, 2010
- A graphical approach to sequentially rejective multiple test proceduresStatistics in Medicine, 2008
- Hy's law: predicting serious hepatotoxicityPharmacoepidemiology and Drug Safety, 2006
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of MigraineNew England Journal of Medicine, 2004
- Migraine — Current Understanding and TreatmentNew England Journal of Medicine, 2002